Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents

被引:3
|
作者
Paradowska-Stankiewicz, Iwona [1 ]
Rumik, Agnieszka [1 ]
Bogusz, Joanna [1 ]
Zbrzezniak, Jakub [1 ]
Rastawicki, Waldemar [1 ]
Smietanska, Karolina [1 ]
Vargas-Zambrano, Juan C. [2 ]
Macina, Denis [2 ]
机构
[1] Natl Inst Publ Hlth, Natl Inst Hyg, Natl Res Inst, Ul Chocimska 24, PL-00791 Warsaw, Poland
[2] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
关键词
Pertussis; Vaccines; Seroprevalence; Waning; REDUCED RISK; IMMUNITY; RECIPIENTS; DURABILITY; EXEMPTIONS; CALIFORNIA; DISEASE;
D O I
10.1016/j.vaccine.2021.08.105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the context of reported resurgence of pertussis in the last decade, researchers hypothesized that acellular (aP) pertussis vaccines elicit a shorter-lived protection compared to whole-cell (wP) pertussis vaccines. However, in the studies seeking to demonstrate this hypothesis, exposure to each vaccine type was not concurrent, and contradictory epidemiologic modeling questioned its validity. The context of pertussis vaccination history in Poland, with both vaccine types used concurrently in comparable proportions, provided an opportunity to investigate this hypothesis. We sought to compare waning of protection by primary series vaccine type by measuring anti-pertussis toxin antibody concentrations as proxy for recent infection. Materials and methods: Serological samples from 2,745 children and adolescents aged >5 years and <16 years and with completed 5-dose pertussis vaccination series were tested by ELISA for pertussis toxin (PT) antibodies. Participants were stratified by type of priming vaccine (wP or aP). Vaccination timeliness and priming-specific trends in anti-PT antibody levels by time since last vaccine dose were analyzed. Results: A total of 1,161 (42.5%) children received wP vaccines, and 1,314 (48.1%) received aP vaccines for their primary series and toddler booster. Overall, 53.57% of the subjects received doses 2-4 in a timely manner, while only 41.52% received all 5 doses at the recommended intervals. Using GMCs or seropositivity measures, both priming groups showed a re-increase in anti-PT antibody levels signing infection in recent years from 8 years after the school-entry booster onward. Comparisons did not show any significant differences between the two groups in the timing or intensity of this re-increase. Conclusion: Our results clearly confirm that vaccine-elicited immunity against pertussis wanes among adolescents even after a complete infant, toddler and school-entry vaccination series. The timing and intensity of the waning of protection appear similar with whole-cell as with acellular pertussis vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:6067 / 6073
页数:7
相关论文
共 50 条
  • [31] COMPARISON OF A 3-COMPONENT ACELLULAR PERTUSSIS-VACCINE WITH WHOLE-CELL PERTUSSIS-VACCINE IN 2-MONTH-OLD CHILDREN
    PICHICHERO, ME
    GREEN, JL
    FRANCIS, AB
    MARSOCCI, SM
    LYND, AM
    LITTEER, T
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (03) : 193 - 196
  • [32] Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis, France, 2013
    Belchior, E.
    Guillot, S.
    Poujol, I
    Thabuis, A.
    Chouin, L.
    Martel, M.
    Delisle, E.
    Six, C.
    Guiso, N.
    Levy-Bruhl, D.
    MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (07): : 617 - 619
  • [33] Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model
    David, S
    van Furth, R
    Mooi, FR
    VACCINE, 2004, 22 (15-16) : 1892 - 1898
  • [34] ASSOCIATION OF REACTIONS AFTER CONSECUTIVE ACELLULAR OR WHOLE-CELL PERTUSSIS-VACCINE IMMUNIZATIONS
    DELORIA, MA
    BLACKWELDER, WC
    DECKER, MD
    ENGLUND, JA
    STEINHOFF, MC
    PICHICHERO, ME
    RENNELS, MB
    ANDERSON, EL
    EDWARDS, KM
    PEDIATRICS, 1995, 96 (03) : 592 - 594
  • [35] Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children
    Vickers, David
    Ross, Allen G.
    Mainar-Jaime, Raul C.
    Neudorf, Cordell
    Shah, Syed
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 175 (10) : 1213 - 1217
  • [36] Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine
    De Serres, G
    Shadmani, R
    Boulianne, N
    Duval, B
    Rochette, L
    Fradet, MD
    Halperin, SA
    VACCINE, 2001, 19 (20-22) : 3004 - 3008
  • [37] Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens
    van den Berg, BM
    David, S
    Beekhuizen, H
    Mooi, FR
    van Furth, R
    VACCINE, 2000, 19 (9-10) : 1118 - 1128
  • [38] Pertussis antibody levels in infants immunized with an acellular pertussis component vaccine, measured using whole-cell pertussis ELISA
    Hanlon, MG
    Nambiar, R
    Kakakios, AM
    McIntyre, P
    Land, MV
    Devine, PL
    IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (03): : 254 - 258
  • [39] A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
    Gustafsson, L
    Hallander, HO
    Olin, P
    Reizenstein, E
    Storsaeter, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06): : 349 - 355
  • [40] Underestimating the Safety Benefits of a New Vaccine: The Impact of Acellular Pertussis Vaccine Versus Whole-Cell Pertussis Vaccine on Health Services Utilization
    Hawken, Steven
    Manuel, Douglas G.
    Deeks, Shelley L.
    Kwong, Jeffrey C.
    Crowcroft, Natasha S.
    Wilson, Kumanan
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 176 (11) : 1035 - 1042